EyePoint DURAVYU Phase 2 VERONA meets primary endpoint in DME; 2.7mg shows +7.1 letter BCVA gain

EyePoint, Inc.

DURAVYU 2.7mg met primary endpoint with extended time to first supplemental injection vs aflibercept.
At week 24, +7.1 letter BCVA gain and 76-micron CST reduction; 73% supplement-free vs 50%.
Favorable safety: no DURAVYU-related ocular or systemic SAEs, no endophthalmitis or retinal vasculitis.
Phase 3 non-inferiority pivotal program planned by end of 2025; FDA meeting in Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.